Cell line · CVCL_3613
Papers48
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Synthesis of 1,2,3-Triazole Derivatives of N,N-Dimethyltryptamine Isolated From Mimosa tenuiflora Root Bark: Antiplasmodial Activity In Silico and In Vitro. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic Significance of S100A4 in Ovarian Clear Cell Carcinoma: Its Relation to Tumor Progression and Chemoresistance. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. | JCI Insight | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. | Gynecol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. | Cancer Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pixelated Microfluidics for Drug Screening on Tumour Spheroids and Ex Vivo Microdissected Tumour Explants. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
Down-regulation of PSMD4 can attenuate autophagy, enhance the accumulation of intracellular ROS, and increase the sensitivity of epithelial ovarian cancer to carboplatin by inhibiting the NF-κB pathway. | Transl Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3613/papers